| Gene Symbol | MMP9 |
| Chromosome | 20q12-13 |
| Protein Family | Matrix metalloproteinase family ( gelatinase B) |
| Protein Type | Protease |
| Target Class | Protease |
| Function | Small molecule zinc-chelating inhibitors or antibody-based inhibition |
| Mechanism of Action | Small molecule zinc-chelating inhibitors or antibody-based inhibition |
| Primary Expression | Secreted, extracellular space, neutrophil granules |
| Druggability | Medium (0.54) |
| Clinical Stage | Phase III |
| Molecular Weight | 92 kDa (pro-MMP9), 82 kDa (active) |
| Amino Acids | 20 aa |
| Pathways | Akt, Apoptosis, Autophagy, Blood-Brain Barrier, Cell Cycle |
| UniProt ID | P14780 |
| GeneCards | MMP9 |
| Human Protein Atlas | MMP9 |
| Associated Diseases | acute-on-chronic liver failure, Aging, ALI, Als, Alzheimer |
| Known Drugs/Compounds | Andrographis paniculata, curcumin, CURCUMIN, doxycycline, Genistein, GENISTEIN |
| Interactions | ABCD1, ABCD2, ADAM15, ADAMTS1, AEP, AGING |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Matrix Metalloproteinase-9-Mediated Claudin-5 Clea Gut dysbiosis-driven monocyte reprogramming toward |
| KG Connections | 1793 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!